Supplementary table 1 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
Year: 2024
Type: supplementary-materials
Abstract: Supplementary table 1: Representativeness of study participants
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4398167333
